Plant-Derived Therapeutics for Androgen Deficiency Syndrome

Hypogonadism, characterized by reduced testosterone levels, is increasingly linked to metabolic disorders such as insulin resistance and hyperglycemia, especially in aging populations. This study aims to explore the interconnection between testosterone deficiency and metabolic dysfunctions and assess the therapeutic potential of phytoconstituents and nutraceuticals in managing androgen deficiency syndrome.

A comprehensive literature review was conducted using various databases, including PubMed, Scopus, Web of Science, and Google Scholar. Relevant studies examining the relationship between hypogonadism and metabolic disorders, and the modulatory roles of phytoconstituents, were analyzed. Phytochemicals such as flavonoids, alkaloids, tannins, carotenoids, and vitamins were reviewed for their effects on androgen levels and insulin sensitivity. The role of novel nutraceutical formulations and advanced drug delivery systems was also evaluated.

Data indicate that 20-64% of males with hyperglycemia suffer from testosterone deficiency. Phytoconstituents have demonstrated potential in modulating multiple metabolic and endocrine pathways. These compounds enhance insulin sensitivity, promote glucose uptake, and support endogenous testosterone synthesis, offering a multi-targeted therapeutic approach.

Phytoconstituents exhibit significant promise in simultaneously addressing hormonal imbalance and metabolic dysfunction. Their multifaceted mechanisms offer advantages over conventional monotherapies. Despite promising preclinical and some clinical evidence, challenges such as limited bioavailability, lack of standardized formulations, and insufficient clinical trials need to be addressed.

This review highlights the therapeutic potential of phytoconstituents and nutraceuticals in treating androgen deficiency and associated metabolic disorders. Future research should prioritize formulation optimization, bioavailability enhancement, and clinical validation.